<\/p>\n
Latest Prevention & Wellness News<\/h3>\n
\n<\/p>\n<\/div>\n
![\"News](\"https:\/\/media.healthday.com\/Images\/icimages\/adult_vaccine10241.jpg\"\/)
By Robin Foster and E.J. Mundell<\/b>
HealthDay Reporters<\/i><\/p>\n
TUESDAY, Sept. 15, 2020 (Healthday News)<\/p>\n
In a sign that Americans are becoming more wary about the safety of a new coronavirus vaccine<\/a>, a new poll shows a majority of adults don’t trust what President Donald Trump has said on vaccine development.<\/p>\n More than half (52%) of adults said they don’t trust the president’s vaccine comments, the NBC News<\/i>\/Survey Monkey poll found, while just 26 percent say they do. Twenty percent said they were “not aware” whether they trust what the president has said about a vaccine, NBC News<\/i> reported.<\/p>\n Those polled were also more skeptical about whether they or their families would get a government-approved coronavirus vaccine if one became widely available, NBC News<\/i> reported.<\/p>\n The poll’s latest data show that just 39% said they would get it, 23% said they wouldn’t and 36 percent say they weren’t sure. Just a month ago, 44% of Americans said they would get a government-approved vaccine, 22% said they wouldn’t, and 32% said they weren’t sure.<\/p>\n The highest level of confidence in a coronavirus vaccine came during the week of Aug. 17 to Aug. 23, when 45% polled said they would get a vaccine.<\/p>\n Despite public hesitancy, President Trump has promised a “safe and effective vaccine this year,” and the U.S. Centers for Disease Control and Prevention<\/a> has advised states to prepare for “large-scale” vaccine distribution by Nov. 1.<\/p>\n Public health experts have questioned that aggressive timeline. Dr. Anthony Fauci, the nation’s leading infectious diseases expert, has said that he feels “cautiously optimistic” that a safe and effective vaccine would be found by the end of the year but that doing so by Nov. 3 was “unlikely,” NBC News<\/i> reported.<\/p>\n Vaccine trials continue<\/b><\/p>\n Meanwhile, Oxford University announced that final-stage testing of a coronavirus vaccine<\/a> it is developing with drug maker AstraZeneca will restart following a pause last week after a serious side effect showed up in a volunteer.<\/p>\n “The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator… the trials will recommence in the U.K.,” the university said in a statement released on Saturday. No further details were given on the results of the review.<\/p>\n Media reports have said the person who had the suspected adverse reaction had been volunteering in a trial based in the United Kingdom. The volunteer was diagnosed with transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections.<\/p>\n The AstraZeneca vaccine is considered a frontrunner among the dozens of coronavirus vaccines<\/a> in various stages of testing around the world, the Associated Press<\/i> reported.<\/p>\n The university said in large trials “it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.” Globally, some 18,000 people have received its vaccine so far, the AP<\/i> reported.<\/p>\n Two other vaccines<\/a> are in final testing in the United States, one made by Moderna Inc. and the other by Pfizer and Germany’s BioNTech.<\/p>\n On Sunday, Pfizer CEO Albert Bourla said the company should soon know whether its vaccine works, CBS News<\/i> reported.<\/p>\n In an interview with “Face the Nation,” Bourla said the Pfizer vaccine trials indicate “we have a good chance that we will know if the product works by the end of October.”<\/p>\n The pharmaceutical giant now plans to expand trial enrollment from 30,000 to 44,000, to test the vaccine in more vulnerable populations, CBS News<\/i> reported.<\/p>\n “Right now, the study recruits from 18 to 85. Now we will go to 16 years old,” Bourla said. “Also, we will go to people with special conditions, chronic conditions like HIV<\/a> patients, but also we will try to use it to increase the diversity of the [study] population.”<\/p>\n Colleges scramble to contain COVID spread<\/b><\/p>\n Just weeks into the fall semester, universities and colleges in all 50 states are struggling to contain the spread of coronavirus on their campuses.<\/p>\n More than 40,000 cases of COVID-19<\/a> have been reported among students, staff and faculty nationwide, CNN<\/i> reported. That number is likely higher due to a lag from schools that update their data every few days.<\/p>\n Many outbreaks have cropped up after gatherings at fraternities and sororities: One cluster of COVID-19<\/a> cases was traced back to a fraternity party held at the University of New Hampshire. More than 100 people attended the Aug. 29 party and few wore masks, CNN<\/i> reported.<\/p>\n At Indiana University Bloomington, 30 sorority and fraternity houses have been ordered to quarantine following what campus officials have described as an “alarming increase” in COVID-19<\/a> cases within the houses, CNN<\/i> reported.<\/p>\n Meanwhile, the University of Wisconsin-Madison has told all undergraduate students they must restrict their movements for the next two weeks, to try to reverse a rise in COVID-19<\/a> cases, CNN<\/i> reported. The university also directed nine campus fraternities and sororities with off-campus live-in houses to quarantine for at least 14 days.<\/p>\n
![](\"https:\/\/images.medicinenet.com\/\/images\/slideshow\/pertussis-whooping-cough-s1-girl-cough-in-bed.jpg\"\/)
![\"MedicalNews\"](\"https:\/\/images.medicinenet.com\/images\/HealthDay\/healthday.png\")
![\"WebMD](\"https:\/\/images.medicinenet.com\/images\/promo\/logo_webmd.gif\"){kind=logo}
<\/h3>\n